Aandeel China SXT Pharmaceuticals, Inc. (SXTC) — is dit een goed bedrijf?

Aandeel China SXT Pharmaceuticals, Inc. (SXTC) — is dit een goed bedrijf? — InspectStocks

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Drug Manufacturers Specialty and Generic

Graded A or B and worth $2B or more: A first, then the largest.

All 78 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Hoe het geld verdient

Regular traditional Chinese medicine pieces95%
Advanced traditional Chinese medicine pieces4%

De omzetaandelen zijn schattingen voor year ended March 31, 2026, geen cijfers uit een ingediend rapport.

Concurreert met

600518Kangmei Pharmaceutical Co., Ltd.
300147Xiangxue Pharmaceutical Co., Ltd.

Wat het verkoopt6

Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.

Nog 3 tonen

SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.

Wie het koopt3

Hospitals, especially traditional Chinese medicine hospitals, buy products for patient care, mainly in Jiangsu province.
Pharmaceutical wholesalers buy products and distribute them to hospitals and other healthcare distributors.
As of March 31, 2026, end customers included 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals (March 31, 2026, high).

Waar het op steunt, en wat het kan breken

Waar het bedrijf van afhangt

1Relies on medicinal-plant raw materials supplied by vendors in China.
2Relies on a limited number of customers; hospitals and pharmaceutical distributors account for important sales channels.
3Its business in China depends on contractual arrangements with Taizhou Suxuantang, a variable interest entity, rather than direct ownership of that operating company.

Wat er mis kan gaan

1Losing or reducing sales to a small number of major customers could harm revenue.
2Disruptions in the supply of medicinal plants or other raw materials could interrupt production and deliveries.
3The company may be unable to enforce its contractual arrangements with Taizhou Suxuantang, or changes in Chinese rules may affect those arrangements or its ability to operate.

Volledige jaarrekening →

Over China SXT Pharmaceuticals, Inc.

China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).

Hoofdkantoor: Taizhou, Jiangsu, China
Opgericht in: 2017
Medewerkers: 56 full-time employees (March 31, 2026, high)
Genoteerd aan: Nasdaq Capital Market
Einde boekjaar: March 31

Gebouwd uit de eigen deponeringen van China SXT Pharmaceuticals, Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.